跳至主要内容
临床试验/NCT01683240
NCT01683240已完成不适用

Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones

Universitätsklinikum Hamburg-Eppendorf5 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2011年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
59
试验地点
5
主要终点
Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis

研究概览

简要总结

Karl Storz GmbH (Gesellschaft mit beschränkter Haftung) company developed a cholangioscopic device, which is designed to give a better flexibility to the cholangioscopy tip in order to enable optimal diagnostic and therapeutic precondition. Other than the conventional mother-baby technique, the insertion of the cholangioscope (baby part) is done by a port at the side of a specially developed duodenoscope (mother part) which is prepositioned distally to the control unit, near to the patient's mouth. Better manoeuverability of the device tip will lead to both a better accuracy in taking biopsies as well as a better flexibility in lithotripsy manoeuvres. This study is designed to test the efficiency of the device in relation to this assumption.

详细描述

Cholangioscopy is a subsidiary treatment in endoscopic retrograde cholangiopancreaticography (ERCP), used for special issues. In the context of ERCP, a long,thin shaped device is introduced through the working channel of a duodenoscope and then through the papilla into the biliary duct.

Inspection of the biliary duct can be used for tumor biopsies as well as for gall stone lithotripsy by laser or electrohydraulic technique.

Manoeuverability of cholangioscopes is limited by the length of the scope, even more, since most of the device body is stuck in the working channel.

The newly designed cholangioscope by the company of Karl Storz GmbH is introduced through a shortened working channel. Introduction of the cholangioscope is done by an innovative side port for the cholangioscope at 70 cm from the insertion tube's distal end. This leads to a better flexibility of the device tip. Better manoeuverability of the device tip will lead to both a better accuracy in taking biopsies as well as a better flexibility in lithotripsy manoeuvres.

This study is designed to test the efficiency of the device in relation to this assumption.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Choledocholithiasis, not treatable through conventional ERCP with sphincterotomy.
  • •Stricture of the biliary duct in need of histopathological investigation

排除标准

  • •Aggravated or impossible access to papilla
  • •Inappropriate biliary anatomy, e.g. multiple strictures or diameter of duct < cholangioscope impairing intubation
  • •Primary sclerosing cholangitis
  • •Coagulopathy (quick < 50%, thrombocytes < 50/nl)and anticoagulant medication
  • •Bad patient's condition (ASA IV)

研究组 & 干预措施

Frimberger cholangioscope

Experimental

Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures

干预措施: cholangioscopy (Frimberger) (Device)

结局指标

主要结局

Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis

时间窗: Patients will be monitored during stay in hospital, average stay is 1 day

1. complete lithotripsy in a single session 2. rate of right positive malignoma diagnostics (sensitivity)

次要结局

  • Complication rate(while examination and 24 hrs past examination)
  • Gallstone therapy(procedure, average procedure time 1 hour)
  • Stricture diagnostic(procedure, average procedure time is 1 hour)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

已完成
不适用
Evaluation of atopic dermatitis using a topical moisturiser containing tocotrienolAtopic dermatitisSkin and Connective Tissue Diseases
ISRCTN45468017ipidware Sdn Bhd30
进行中(未招募)
不适用
A multicentre, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory multiple myelomaPreviously treated subjects with relapsed/refractory multiple myelomaMedDRA version: 8.1Level: PTClassification code 10028228Term: Multiple myeloma
EUCTR2006-002517-12-IECelgene International Sarl1,400
进行中(未招募)
1 期
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0Level: LLTClassification code 10064677Term: Graft versus host disease in intestineSystem Organ Class: 100000004870MedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 100000004870
EUCTR2018-003296-35-LTovartis Pharma AG42
进行中(未招募)
2 期
A phase 2 trial of Ruxolotinib in pediatric patients with moderate and severe chronic graft vs host disease
CTRI/2019/11/021974ovartis Healthcare Pvt Ltd
进行中(未招募)
1 期
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 100000004870MedDRA version: 20.0Level: LLTClassification code 10064677Term: Graft versus host disease in intestineSystem Organ Class: 100000004870
EUCTR2018-003296-35-SKovartis Pharma AG42
Prospective Multicenter Evaluation of a New... | 临床试验